REGENXBIO Swings to Q2 Profit on $100M AbbVie Milestone, Extends Cash Runway into Q4 2027

summarizeSummary

Driven by a $100 million AbbVie milestone, REGENXBIO reported Q2 2026 net income of $22.7 million and disclosed over $200 million in new July capital, extending its cash runway into Q4 2027. Key pipeline milestones remain on track, including a Duchenne BLA submission this quarter and pivotal wet AMD data in Q4.

check_boxKey Events · Earnings and Guidance · RGNX

• Q2 Profit Driven by $100M Milestone

  Net income reached $22.7 million ($0.43 per share), a sharp turnaround from the $70.9 million net loss a year ago, primarily fueled by a $100 million AbbVie milestone for dosing the first patient in the NAAVIGATE diabetic retinopathy study.

• Cash Runway Extended into Q4 2027

  Pro forma cash stood at approximately $313 million as of June 30, 2026, incorporating the $100 million milestone and $108 million in net proceeds from a July 2026 equity offering, funding operations into the fourth quarter of 2027.

• Duchenne BLA Submission on Track for Q3 2026

  Initiation of the RGX-202 BLA submission is expected in Q3 2026 under the accelerated approval pathway, with potential approval in the second half of 2027.

• Pivotal Wet AMD Data Expected in Q4 2026

  Topline data from the ATMOSPHERE and ASCENT pivotal trials of sura-vec for wet AMD are expected in Q4 2026, with global regulatory submissions planned for 2027.

auto_awesomeAnalysis · RGNX · Life Sciences

A $100 million milestone payment from AbbVie transformed the quarter, driving net income to $22.7 million and reversing a year-ago loss. Combined with a $108 million equity raise in July, pro forma cash now exceeds $310 million, funding operations into Q4 2027. The balance sheet is materially de-risked, and multiple near-term catalysts are set: the Duchenne gene therapy BLA submission remains on track for Q3 2026, with pivotal wet AMD data due in Q4 2026.